INMB FY 2021 Earnings — INmune Bio, Inc. Revenue & Financial Results | Market Cap Arena

INMBINmune Bio, Inc.

$37M

FY 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$181,000+1545.5% YoY

Gross Profit

$181,000100.0% margin

Operating Income

-$29M-16106.6% margin

Net Income

-$30M-16762.4% margin

EPS (Diluted)

$-1.88

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$44M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$100M

Total Liabilities

$20M

Stockholders' Equity

$80M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$181,000	$11,000	+1545.5%
Gross Profit	$181,000	$11,000	+1545.5%
Operating Income	-$29M	-$12M	-138.4%
Net Income	-$30M	-$12M	-150.8%